Montelukast Bluefish

Montelukast, the active ingredient in Montelukast Bluefish, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in both adults and children.

GNH USA supplies Montelukast Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic airway diseases.

Asthma: provides maintenance therapy that reduces the frequency and severity of asthma attacks. Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal allergies. Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during physical exertion.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Mood changes, including suicidal thoughts or behavior

When prescribing Montelukast, clinicians should consider several safety aspects.

Assess liver function: monitor patients with pre‑existing hepatic disease. Review psychiatric history: observe for mood alterations or suicidal ideation. Avoid use in patients with known hypersensitivity to montelukast or its excipients. Use caution in severe renal impairment: dose adjustment may be required. Store at ambient temperature: keep in the original container, protect from moisture and heat.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Rifampin: induces metabolism, lowering montelukast levels. - Ketoconazole: inhibits metabolism, raising drug concentrations. - Phenobarbital: induces hepatic enzymes, decreasing effectiveness.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR values. - Theophylline: may increase plasma concentrations. - Beta‑agonists: potential reduction of bronchodilator response.